Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Oil Bulls Attempt to Repair Yesterday’s Damage

We have seen a pretty sharp oil reversal yesterday. The U.S. session sent oil bulls packing. Not giving up, they’re attempting a comeback today. Geopolitical news to their rescue: the drone attacks on key Saudi pipelines. Emboldened by this tailwind, do the oil...
Nadia Simmons | May 14, 2019 |

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. ...
Streetwise Reports | November 25, 2019 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

Buzz on the Bullboards: Mining, tech and cannabis make waves

Canada’s main stock index started the week on a positive note after a rough performance last week, only to pivot downward throughout the following days, suffering declines across major sectors. The Bank of Canada’s reduction of its target ...
Jonathon Brown | July 25, 2024 |

The EV Battle is Heating Up: Enter “The Tesla Killer”

(IoniX Pro Home Smart Wall Product Rendering via Extreme Vehicle Battery Technologies Corp.) When it comes to the Electric Vehicle (EV) revolution, the future is imminent and those who have adopted this next level lifestyle agree that what they need is power … an...
Stockhouse Editorial | January 11, 2021 |

Why Trump’s low-dollar plan won’t work

The slowdown in the United States, and throughout the world, has led many to speculate that the time has come for an intervention in the US economy. Despite a healthy stock market and the economy barreling along at near full employment , persistent negative economic in...
Richard (Rick) Mills | July 31, 2019 |

NAI500 Special Report: EV Battery Tech Went Up 487.5% in One Week!

Extreme Vehicle Battery Technologies Corp. ( CSE: ACDC, Forum ) had an amazing first week of 2021 after they announced their Home Smart Wall, the first product of their IoniX Pro Home Smart Wall series. Moving from $0.035 to $0.25 in less than 5 days, the company has capt...
Featured Submission | January 13, 2021 |

Will Job Market from Hell Support Gold?

April job report shows a terrible US labor market. Coronavirus destroyed 20.5 million jobs, pushing the unemployment rate to almost 15 percent. How far does the number reflect reality – and what does it actually mean for the gold market? Apocalypse in the US Labor Market ...
Arkadiusz Sieron | May 13, 2020 |

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

A description of the asset and its potential are provided in a Dawson James report. In a July 11 research note, Dawson James Securities analyst Jason Kolbert reported that coverage of DelMar Pharmaceuticals Inc. (DMPI:NASDAQ) transferred to him and, subseq...
Streetwise Reports | July 19, 2019 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |
1 2 3 4 5 6 7 8 9 10 ...